This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Einhorn, L. H. Search for Related Content PubMed PubMed Citation Articles by Einhorn, L. H.

Testicular Cancer as a Model for a Curable Neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture¹

Department of Medicine, Indiana University Medical Center, and Veterans' Administration Hospital, Indianapolis, Indiana 46223

The combination of platinum, vinblastine, and bleomycin was first used at Indiana University in 1974. Thirty of 47 patients (64%) survived for 5 years, and 27 (57%) are currently disease free (NED) and cured of their neoplasm.

From 1976 to 1978, 78 consecutive patients were entered on a random prospective study that indicated that equal therapeutic results could be achieved with a lower dosage (0.3 mg/kg) of vinblastine. Fifty-two (67%) patients are continuously NED, and 57 (73%) are currently NED for 2 or more years.

Our third-generation study, done in conjunction with the Southeastern Cancer Study Group, tested the hypothesis of whether maintenance vinblastine was necessary to ensure optimal cure rates in disseminated testicular cancer. One hundred thirteen patients entered this maintenance study, and the results demonstrated that cure in a far-advanced cancer could be achieved with only 12 weeks of therapy (remission induction) because the relapse rate in such patients was only 7%. The cure rate for patients presenting with locoregional disease (Stages A and B) should approach 100%.

Platinum, vinblastine, and bleomycin will regularly produce a 70% complete remission rate, and a further 10% of patients will be rendered NED with surgical resection of residual disease. The relapse rate with four courses of remission induction therapy in a large cooperative group study (Southeastern Cancer Study Group) was only 7%.

The high success rate in disseminated disease has allowed the option of high cure rate in Stage B disease (positive retroperitoneal nodes) with or without adjuvant chemotherapy. At Indiana University, 137 patients have been followed with Stage A and B nonseminomatous testicular cancer from 1973 to 1979 with a minimum follow-up of 2 years, and currently 135 are alive and well. Successful treatment strategies in testicular cancer have yielded a cure rate unparalleled in cancer treatment.

¹ Presented in part at the 1981 Meeting of the American Association for Cancer Research in Washington, D. C. Supported in part by USPHS Grant M01 RR00 750-06 and Southeast Cancer Study Group Grant CA-19657.

² American Cancer Society Professor of Clinical Oncology.

Received 5/20/81. Accepted 6/ 9/81.

This article has been cited by other articles:

				A. Horwich Stage I seminoma and carboplatin risks Ann. Onc., March 1, 2008; 19(3): 407 - 408. [Full Text] [PDF]